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Abstract: Different steps and conditions for DNA extraction for microbiota analysis in sputum
have been reported in the literature. We aimed at testing both dithiothreitol (DTT) and enzymatic
treatments of sputum samples and identifying the most suitable DNA extraction technique for the
microbiota analysis of sputum. Sputum treatments with and without DTT were compared in terms of
their median levels and the coefficient of variation between replicates of both DNA extraction yield
and real-time PCR for the 16S rRNA gene. Treatments with and without lysozyme and lysostaphin
were compared in terms of their median levels of real-time PCR for S. aureus. Two enzyme-based and
three beads-based techniques for DNA extraction were compared in terms of their DNA extraction
yield, real-time PCR for the 16S rRNA gene and microbiota analysis. DTT treatment decreased
the coefficient of variation between replicates of both DNA extraction yield and real-time PCR.
Lysostaphin (either 0.18 or 0.36 mg/mL) and lysozyme treatments increased S. aureus detection.
One enzyme-based kit offered the highest DNA yield and 16S rRNA gene real-time PCR with
no significant differences in terms of alpha-diversity indexes. A condition using both DTT and
lysostaphin/lysozyme treatments along with an enzymatic kit seems to be preferred for the microbiota
analysis of sputum samples.
Keywords: DNA extraction; sputum; microbiota; sequencing
1. Introduction
The study of the human microbiome has emerged as an important field in translational research
over the past decade, and promising applications of this technique in clinical practice have been
Int. J. Mol. Sci. 2018, 19, 3256; doi:10.3390/ijms19103256 www.mdpi.com/journal/ijms
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suggested [1]. Most of the recent advances in microbial ecology have been made possible thanks to
the development of next-generation sequencing technologies which allow the analysis of complex
microbial populations in different body niches, including the respiratory tract. Multiple studies of
the human-associated microbiota have suggested a fundamental role of microbes, and predominantly
bacteria, in maintaining health and a role for changes in lung microbiota in contributing to diseases
such as chronic obstructive pulmonary disease (COPD), bronchiectasis and cystic fibrosis (CF) [2–7].
Most of the published literature evaluating microbiota in chronic respiratory infections has used
sputum as the preferred sample type. Although potentially less representative of the deep lung as
compared with bronchoalveolar lavage (BAL), sputum could represent the preferred non-invasive
diagnostic technique to be used in clinical practice for microbiota analysis. However, metagenomic
sequencing from sputum is challenging because of the complex matrix of sputum, its heterogeneity,
the activity of proteases and nucleases and the variability in sputum quality. Little has been published
regarding the optimal methods for nucleic acid extraction from sputum for use in microbiome studies.
Some bacteria require high levels of mechanical disruption or enzymatic disruption in order to achieve
efficient lysis, and these include important pathogens in bronchiectasis and cystic fibrosis such as
Staphylococcus aureus. [8,9].
Different techniques have been used so far for microbiota analysis in respiratory samples,
resulting in heterogeneity in terms of sample processing for DNA extraction, library preparation and
bioinformatics analysis [4,10]. With a view to being able to compare the results of respiratory microbiota
studies from different cohorts and different diseases, this heterogeneity needs to be approached, and
optimal operating procedures to evaluate microbiota from sputum should be identified. Several steps
should be standardized, including the use or not of fluidifying agents, such as dithiothreitol (DTT), or
enzymes for specific bacterial lysis, such as lysozyme and lysostaphin for S. aureus, as well as different
methods for DNA extraction and isolation. Although a comparison between different methods for
DNA extraction in both BAL and gastrointestinal samples has already been carried out, no previous
studies have specifically addressed this topic for sputum samples [11,12].
The present study had three objectives: (1) to evaluate the performance of DTT treatment to
homogenize sputum samples; (2) to evaluate the effect of an enzymatic step for Gram-positive lysis;
and (3) to investigate the performance of lytic chemical/enzyme-based and bead-based extraction kits.
2. Results
Study patients. A total of 32 adult patients with CF and bronchiectasis were enrolled in this study,
and 77 sputum samples were collected for the three experiments.
Experiment 1—DTT treatment evaluation. The median values of extracted DNA were similar
between the DTT-untreated and DTT-treated group (16.630 vs. 17.880 µg, p = 0.7211) (Figure 1a).
The coefficient of variation between replicates was statistically lower in sputa treated with DTT in
comparison with not-treated aliquots (DTT-untreated 0.1014 vs. DTT-treated: 0.0592, p = 0.018),
(Figure 1b). A similar situation has been identified when the analysis of the 16s real-time PCR
was performed (Figure 1c,d). Although no differences were detected between groups in terms of
their median Ct (DTT-untreated: 19.93 vs. DTT-treated: 20.09, p = 0.519), there was a statistically
significant decrease of the coefficient of variation in the DTT group compared to the not-treated one
(DTT-untreated: 0.01859 vs. DTT-treated: 0.008848, p = 0.013).
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samples. Significantly high bacterial loads of S. aureus, represented by significantly lower median Ct 
levels by real-time polymerase chain reaction (PCR), were identified in samples treated with lytic 
enzymes compared with the non-treated ones (p = 0.038 for lysostaphin 0.18 mg/mL and lysozyme 
3.6 mg/mL; p = 0.027 for lysostaphin 0.36 mg/mL and lysozyme 3.6 mg/mL). No significant difference 
was identified between the median levels of Ct among samples treated with the two dosages of 
lysostaphin and lysozyme (p = 1) (Figure 2). 
Experiment 3—Evaluation of different kits for bacterial DNA extraction. DNA extraction 
yield reached the highest values using the Roche kit in comparison to all the other kits. The median 
(interquartile range, IQR) yields for DNA extracted with the five kits were as follows: Roche 16,250 
ng (6100–33,500 ng); Zymo Universal 12,350 ng (6225–23,750 ng); Zymobiomics 5975 ng (2625–13,000 
ng); QIAGEN 1913 ng (204.5–10,475 ng); and Mobio 1205 ng (4.1–23,000 ng). Significant differences 
were found across the five kits (p < 0.0001) and between two or more kits (Figure 3). No statistical 
differences were found between Roche and Zymo Universal in terms of DNA recovery (p = 0.3506). 
Results from the 16s rRNA gene Real-Time PCR showed a similar median Ct across the five 
extraction methods (p = 0.169). The median (IQR) Ct values were as follows: Roche 16.57 (12.01–
22.94); Zymo Universal 17.29 (13.42–23.55); QIAGEN 17.86 (14.45–21.22); Mobio 18.87 (13.16–22.72); 
and Zymobiomics 19.57 (10.04–24.85). The only significant difference was found between Ct values 
obtained using the Roche and Zymobiomics kits (p = 0.027). 
Figure 1. Comparison of median levels of (a) DNA extraction yield, (b) coefficient of variation between
replicates, (c) 16s rRNA gene real-time PCR results, and (d) coefficient of variation between replicates
across dithiothreitol (DTT)-untreated sputum vs. DTT-treated (Experiment 1).
Experiment 2—Lytic enzymes evaluation. S. aureus was detected from all the evaluated samples.
Significantly high bacterial loads of S. aureus, represented by significantly lower median Ct levels
by real-time polymerase chain reaction (PCR), were identified in samples treated with lytic enzymes
compared with the non-treated ones (p = 0.038 for lysostaphin 0.18 mg/mL and lysozyme 3.6 mg/mL;
p = 0.027 for lysostaphin 0.36 mg/mL and lysozyme 3.6 mg/mL). No significant difference was
identified between the median levels of Ct among samples treated with the two dosages of lysostaphin
and lysozyme (p = 1) (Figure 2).
Experiment 3—Evaluation of different kits for bacterial DNA extraction. DNA extraction yield
reached the highest values using the Roche kit in comparison to all the other kits. The median
(interquartile range, IQR) yields for DNA extracted with the five kits were as follows: Roche 16,250 ng
(6100–33,500 ng); Zymo Universal 12,350 ng (6225–23,750 ng); Zymobiomics 5975 ng (2625–13,000 ng);
QIAGEN 1913 ng (204.5–10,475 ng); and Mobio 1205 ng (4.1–23,000 ng). Significant differences were
found across the five kits (p < 0.0001) and between two or more kits (Figure 3). No statistical differences
were found between Roche and Zymo Universal in terms of DNA recovery (p = 0.3506).
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Figure 3. Comparison of median levels of (a) DNA extraction yield and (b) bacterial extraction 
efficiency across the five analyzed commercial kits. Kruskal–Wallis test: DNA extraction p < 0.0001; 
16s rRNA gene real-time PCR p = 0.169. Mann–Whitney test: *: p ≤ 0.001; **: p ≤ 0.0009, *** p ≤ 0.0001; #: 
p = 0.027 (Experiment 3). 
A low number of joined reads (min 47–max 253) was produced for each negative control and no 
bacteria were identified. None of the operational taxonomic units (OTUs) assigned to these samples 
passed the 0.5% prevalence threshold that was set to filter out low-abundance OTUs from the OTU 
table considered to be due to cross-talk or experimental error. 
The sequencing depth was nearly the same for all samples which were extracted with the 
different kits (typical number of reads comprised between 0 and 100,000), except for one. One 
sample extracted with Zymobiomics was sequenced ~ 7 times more deeply than all the others 
(Figure 4). 
The only sample we were not able to sequence belonged to the Mobio group. 
Figure 2. Comparison of median levels of real-time PCR for S. aureus across samples treated with
lysostaphin at either 0.18 or 0.36 mg/mL and lysozyme (3.6 mg/mL) or without lytic enzymes treatment.
Results expressed in cycle threshold (Ct). Kruskal–Wallis test: p = 0.041 (Experiment 2).
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Figure 3. Comparis n of median levels of (a) DNA extraction yield and ( ) bacterial extraction
efficiency across the five analyzed co mercial kits. Kruskal–Wallis test: extractio p < 0.0001; 16s
rR gene real-ti e p 0.169. ann—Whitney test: *: p ≤ 0.001; **: p ≤ 0.0009, *** p ≤ 0.0001;
#: p = 0.027 (Experiment 3).
Results from the 16s rRNA gene Real-Time PCR showed a similar median Ct across the five
extraction methods (p = 0.169). The edian (IQR) Ct values were as follows: Roche 16.57 (12.01–22.94);
Zymo Universal 17.29 (13.42–23.55); QIAGEN 17.86 (14.45–21.22); Mobio 18.87 (13.16–22.72); and
Zymobiomics 19.57 (10.04–24.85). The only significant difference was found between Ct values
obtained using the Roche and Zymobiomics kits (p = 0.027).
A low number of joined reads (min 47–max 253) was produced for each negative control and no
bacteria were identified. None of the operational taxonomic units (OTUs) assigned to these samples
passed the 0.5% prevalence threshold that was set to filter out low-abundance OTUs from the OTU
table considered to be due to cross-talk or experimental error.
The sequencing depth was nearly the same for all samples which were extracted with the different
kits (typical number of reads comprised between 0 and 100,000), except for one. One sample extracted
with Zymobiomics was sequenced ~7 times more deeply than all the others (Figure 4).
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The relative abundances of the 15 samples were measured using the five evaluated kits and are
presented in Figure 6 along with the results of cultures from standard microbiology. The comparison
between genera retrieved through 16S rRNA gene sequencing and culture results showed a complete
concordance of the two techniques at the genus level, even if, as expected, 16S rRNA sequencing
allowed us to identify a broader range of bacteria. Each technique seems to be able to extract bacterial
genera in a similar way.
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3. Discussion
Our study indicates that the High Pure PCR Template Preparation (Roche) kit preceded by both
DTT and enzymatic digestion steps offers a higher DNA yield and more 16S rRNA gene real-time
PCR extracted from sputum samples in comparison to the other evaluated conditions (Figure 3).
Furthermore, no significant differences in terms of alpha-diversity (i.e., Shannon, Simpson and richness
indices) have been detected across the different methods evaluated (Figure 5).
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A previous pilot study showed that no negative effect derived from the use of enzymes, DTT and
different kits was identified. Variables were evaluated simultaneously, but a single variable approach
is needed in order to have a deep understanding of single variables’ contributions [13]. For this reason,
a consecutive approach has been adopted for the present study in order to understand the unique
contribution of three different interventions: the use of DTT, the introduction of an enzymatic step and
the choice of the best DNA extraction kit.
The reactive sulphydryl groups of DTT have a mucolytic function and are used to reduce
mucoprotein disulfide bonds. DTT is commonly used in standard microbiology to homogenize
sputum samples, enhancing the isolation of microorganisms, and has been also adopted in different
studies for microbiota analysis [14,15]. Sputum heterogeneity is one of the most challenging aspects of
bacterial DNA recovery, especially in patients with CF and bronchiectasis. We evaluated the use of DTT
through 16s rRNA real-time PCR in terms of (1) median levels, in order to understand if the presence
of DTT was increasing bacterial DNA recovery; and (2) the coefficient of variation between replicates,
in order to understand if the presence of DTT was able to better homogenize sputum and increase
data reproducibility (Figure 1). The use of a reducing agent to treat this matrix allows the release of
those bacteria entrapped in sputum plugs. We demonstrated that the addition of DTT increases the
reproducibility of the data and facilitates sputum handling without affecting DNA extraction.
Lysostaphin and lysozyme have been extensively used in the literature to increase DNA recovery
from Gram-positive bacteria [16–18]. These enzymes specifically lyse cell walls and ensure DNA
recovery. Previously published experiences demonstrated clear advantages in adding lytic enzymes,
including lysozyme and lysostaphin, to sputum samples. Cell wall destruction determined by the
addition of these products improves real-time PCR detection and the sequencing of some Gram-positive
bacteria, such as S. aureus, and this is evident already at low enzyme concentrations (lysostaphin at
0.18 mg/mL) [5]. Williamson and colleagues demonstrated the need to introduce these agents for
microbiome analysis, even if there is no agreement in the literature on the concentration of lysostaphin
needed to lyse bacteria in sputum samples. We demonstrated that sputum processing using these
enzymes increases S. aureus DNA recovery, while the increase of lysostaphin concentrations seems not
to affect S. aureus detection (Figure 2). Even if the presence of both pre-treatments will increase the
time and costs of bacterial DNA extraction from sputum, the addition of this step seems to be needed
in order to have more reliable and reproducible data.
We decided to use the Zymo Universal kit according to a previously performed pilot study [13]
which compared different commercial kits across all conditions (with and without DTT and enzymes)
in order to understand if combining/interfering effects were present among different variables. In this
instance, we found no combined effect derived from the use of enzymes and DTT in terms of DNA
yield, 16s rRNA gene and the S. aureus real-time PCR cycle threshold and microbiota analysis.
Studies evaluating respiratory microbiota in COPD and bronchiectasis patients used either BAL,
spontaneous sputum or induced sputum [19–22]. DNA extraction methods across these experiences
have been very heterogeneous, with some authors using chemical methods [14], others bead beating
methods [23] and others a combination of physical lysis and methods such as phenol-chloroform [22].
The use of a combination of chemical and enzyme-based lysis increases DNA recovery from sputum
samples. This method reduces the possibility of losing material after lysis because the whole of the
lysate from samples is transferred into the DNA purification column. When bead-beating techniques
are used, a fraction of lysate is retained in the beads phase after centrifugation. Even if Mobio,
Zymobiomics and QIAGEN are based on mechanical disruption through bead beating, differences in
methods could explain differences in extracted DNA yield. As reported in Table 1, Zymobiomics and
QIAGEN also expose samples to enzymatic digestion in order to increase DNA extraction. Moreover,
beads sizes differ between kits: QIAGEN and Mobio present glass beads of 0.1 mm of size, while
Zymobiomics has beads of both 0.1 and 0.5 mm of size. Finally, column filters and reagents are specific
for each kit. In terms of microbiota analysis, we were not able to identify statistically significant
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differences across the used kits, and we can therefore speculate that all the evaluated kits perform
equally in representing analyzed samples (Figures 5 and 6).
No similar studies have been previously designed and published to evaluate different DNA
extraction methods from sputum to microbiota evaluations. Because of this, we were not able to
define the correct sample size of our study a priori which should be interpreted as a pilot in its nature.
Moreover, samples were tested in duplicate in real-time PCR (not triplicate) due to the low DNA yield
of some samples. In the present study, we were not able to evaluate other methods for DNA extraction,
including boiling, phenol-chloroform or automatic extraction, which have been previously reported in
the literature, although the ones we have considered are those commercially available [14,22].
This is the first study able to evaluate different steps for DNA extraction from sputum for
microbiota analysis in a sequential process which permits us to better control the impact of different
interventions. The final evaluation consisted of the microbiota analysis of all the possible final
conditions in order to have a general overview of the method. The use of blanks from each step and a
positive control to increase the reliability of the sequencing techniques allowed us to exclude kits and
environmental bacterial contamination.
4. Materials and Methods
Three sequential experiments were performed to specifically address the study objectives. Sputum
samples were collected from 32 adults with either CF or bronchiectasis referring to the Respiratory
Department of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, between
February and March 2018. Subjects signed an informed consent form and gave their approval to use
their samples for the purpose of this study. Aliquots of sputum were collected and stored at −80 ◦C
for all subsequent analyses, after which extraction samples were thawed and 0.1 g of sputum plug was
selected for extractions.
Standard cultures for bacteria, fungi and non-tuberculous mycobacteria were performed by our
local Cystic Fibrosis laboratory in accordance with the CF Foundation guidelines [24]. 100 microliters
of the samples were plated on complete and selective media to isolate all potential pathogenic
microorganisms. In the case of growth of potential pathogens, the colony morphotypes observed on
the selective and non-selective media were identified by colonial morphology, pigment production
or β-haemolysis, and then by biochemical assays and/or proteomic profiling by matrix assisted laser
desorption-time of flight mass spectrometry (MALDI-TOF MS). After that, antibiotic susceptibility
tests were performed by the Microscan WalkAway plus System (Beckman Coulter, Brea, CA, USA) [15].
Experiment 1—DTT Treatment Evaluation. In order to evaluate the need for sample
homogenization, a total of 10 patients were enrolled in this experiment and 55 sputum samples
were collected. Each sample was divided into two aliquots: the first aliquot was treated 1:1 with
DTT (Sputafluid, Biolife, Italy) following the manufacturer’s instructions (DTT solution 10%, vortexed
and left at room temperature for 15 min), while the second one received no treatment. After that,
DNA was extracted in duplicate using Zymo Quick-DNA Universal Kit (Zymo, Irvine, CA, USA)
according to the manufacturer’s instructions and eluted in 50 µL elution buffer. DNA extraction yield
was measured through quantification by the Quant-iT dsDNA Assay Kit High Sensitivity and Qubit
3.0 Fluorometer (Invitrogen, Carlsbad, CA, USA). Subsequently, samples were diluted at 5 ng/µL to
avoid the inhibition of PCR due to the high concentration of human DNA and tested through real-time
PCR for SYBR Green for 16S rRNA gene amplification [25]. Each sample was tested in duplicate and
the cycle threshold (Ct) means between replicates, standard deviation and coefficient of variation were
considered in order to identify potential differences between replicates. Endpoints for this experiment
were real-time PCR for the 16S rRNA gene and coefficient of variation, as well as DNA yield and
coefficient of variation. The DNA yield and 16S rRNA gene real-time PCR of the two groups identified
as DTT-untreated and DTT are presented as a median with interquartile range (IQR). The coefficient of
variation as the ratio of the standard deviation to the mean was calculated. The Mann–Whitney test
was applied between groups.
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Experiment 2—Lytic enzymes evaluation. In order to understand if lysis using lysostaphin and
lysozyme would increase sensitivity for specific genera, sputum samples from seven patients in which
S. aureus had been isolated according to standard microbiology were selected and treated with DTT
according to the results of Experiment 1. The enzymatic digestion was inserted in the procedure
immediately after DTT treatment, carried out with lysozyme at 3.6 mg/mL and lysostaphin in two
different conditions: 0.18 and 0.36 mg/mL (Sigma-Aldrich, Saint Louis, MO, USA). Samples were
incubated at 37 ◦C for 30 min prior to DNA extraction. DNA extraction and DTT treatment were
carried out as reported above. Real-time PCR for S. aureus was conducted on DNA extracts as already
described [26]. Data were divided into three groups: (i) no lysostaphin; (ii) lysostaphin 0.18 mg/mL
and (iii) lysostaphin 0.36 mg/mL, which are presented as medians (IQR). The endpoint included
real-time PCR for S. aureus. Mann–Whitney and Kruskal–Wallis tests were applied to the three groups.
Experiment 3—Evaluation of different kits for bacterial DNA extraction. Fifteen samples were
analyzed to understand which is the most suitable technique to extract DNA from sputum. Samples
were pretreated according to Experiment 1 and 2 (DTT treatment and lysostaphin 0.18 mg/mL and
lysozyme 3.6 mg/mL) and DNA was extracted using five different commercial kits: (1) Roche High
Pure PCR Template Preparation Kit (Hoffmann, La Roche, Basel, Switzerland); (2) Zymo Quick-DNA
Universal Kit (Zymo, Irvine, CA, USA); (3) MoBio PowerLyzer PowerSoil DNA isolation kit (Mobio,
Loker Ave West, Carlsbad, CA, USA), actually sold by QIAGEN as the Qiagen DNeasy PowerSoil
kit; (4) QIAGEN QIAmp Cador Pathogen Mini kit (Qiagen, Hilden, Germany); (5) ZymoBIOMICS
DNA Miniprep Kit (Zymo, Irvine, CA, USA) (Table 1). The first two methods use the combination of
both chemical and enzyme-based lysis, while the other three use a mechanical destruction through
bead-beating. Commercial kits were used according to the manufacturer’s instructions and DNA was
eluted in 50 µL elution buffer. DNA extraction was carried out as previously described, as well as
real-time PCR targeting the 16s rRNA gene. The microbiota evaluation procedure is reported below.
Negative controls from each DNA extraction kit and from PCR were also sequenced in order to also
evaluate environmental contamination in kit reagents.
Microbiota evaluation. The V3-V4 variable regions of the 16S rRNA gene were amplified
from DNA extracts using the 16S metagenomic sequencing library preparation protocol (Illumina,
San Diego, CA, USA). PCR products, approximately sized 630 base pairs, were visualized using
microfluidics-based gel electrophoresis on Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA) and then
were cleaned using AMPure XP magnetic bead-based purification (Beckman Coulter, Brea, CA, USA).
Sample libraries were quantified using the Qubit as reported above and then pooled in an equimolar
mode. Finally, the pool was sequenced on the MiSeq (Illumina, San Diego, CA, USA) sequencing
platform, using a 2 × 300 cycle V3 kit and following standard Illumina sequencing protocols.
Bioinformatic and statistical analyses. Demultiplexed paired-end reads in the FASTQ format
were received from the Illumina MiSeq instrument. Sequencing data were processed following the
UPARSE pipeline by Edgar [27], using USEARCH v10.0.240 (Tiburon, CA, USA) [28] and VSEARCH
v2.3.4 (Oslo, Norway) [29]. Overall run quality was checked using FastQC v0.11.2 (Cambridge, UK) [30]
and reports were summarized using MultiQC v1.4 (Stockholm, Sweden) [31]. Quality scores dropped
towards the end of the reverse reads, so they were globally trimmed at position 275 before merging
with the corresponding forward reads. Parameters for paired-end reads merging were set as follows: a
minimum overlapping length of 95 base pairs, a minimum 90% identity of alignment, and the merged
sequence lengths were restricted to 432–482 bases. Consensus sequences from all samples were pooled
together and primers were stripped from both ends. This “raw” set of merged sequences was then
quality-filtered and de-replicated to obtain a subset of high-quality unique sequences to be clustered
into operational taxonomic units (OTUs). Sequences with more than one expected number of errors
(EE) were discarded and singletons removed during de-replication. OTUs were clustered at a 97%
identity threshold. The taxonomy prediction at the genus level for OTU sequences was performed
via the SINTAX algorithm [32], using the RDP training set v16 as the reference database and 0.8 as
confidence threshold. An OTU table was constructed by mapping the whole set of “raw” merged
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paired-end reads to the representative set of OTUs, using a 97% identity threshold. It was then filtered
for low-abundance OTUs (<0.5 overall frequency), which were discarded, and normalized to the same
number of reads per sample. This OTU table was used for all downstream analyses. Alpha diversity
was measured for each sample using different metrics (Shannon entropy, Simpson estimators, and
richness). These indices were then converted to the effective number of species (ENOS) [33] to be easily
compared to each other. Results at the genus level were considered. Data were divided in five groups
depending on the DNA extraction technique and presented as median (IQR). Sequences have been
uploaded to the Sequence Read Archive (SRA) and are available under the project ID PRJNA488913.
Endpoints included the DNA yield, real-time PCR for the 16S rRNA gene and alpha indices (Shannon
and Simpson expressed as indices and as ENOS, and richness). Furthermore, a relative abundances
comparison with standard microbiology was conducted. Mann–Whitney and Kruskal–Wallis tests
were applied. A significance level of 0.05 was used for all the three experiments using GraphPad
Prism 5 (La Jolla, CA, USA).
Table 1. Comparison of different methods for DNA extraction (Information provided by manufacturer’s
instructions and protocols).
Method Basis of Function Cost per Sample Time per Sample (min) Advantages Disadvantages Reference
Roche High Pure
PCR Template
Preparation Kit
Lysis Buffer and
proteinase K digestion 2.62 € 16
Easy to use and
quick protocol.
Milder extraction
method than
mechanical
Feigelman et al. 2017 [34]
Zymo Quick-DNA
Universal Kit
Lysis Buffer and
proteinase K digestion 2.49 € 18
Easy to use and
quick protocol
Milder extraction
method than
mechanical
Blow et al. 2017 [35]
MoBio PowerLyzer
PowerSoil DNA
isolation kit
Bead beating 6.16 € 41 Possibility to lysehard-to-lyse bacteria
Time consuming,
possibility of DNA loss
because of high number
of steps
Willner et al. 2012 [36]
QIAGEN QIAmp
Cador Pathogen
Mini kit
Bead beating and
proteinase K digestion 4.6 € 20
Possibility to lyse
hard-to-lyse bacteria.
Possibility to combine
different methods.
Possibility of DNA loss Hart et al. 2015 [37]
ZymoBIOMICS
DNA Miniprep Kit
Bead beating and
proteinase K digestion 5.12 € 63
Combination of
enzymatic and
mechanical distruption.
Option to use
different protocols
Time consuming,
possibility of DNA loss
because of high number
of steps
Sohrabi et al. 2016 [38]
5. Conclusions
In conclusion, the use of the Roche kit with the addition of a DTT treatment and enzymatic
digestion with lysostaphin (0.18 mg/mL) and lysozyme offers better performance in terms of
DNA yield and 16S rRNA gene real-time PCR extracted from sputum samples in comparison to
other conditions.
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